RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.